Keyword: Teva Pharmaceutical
Teva is working to consolidate seven U.S. offices under one roof, and that means saying bye-bye to its New York and Washington, D.C., locations.
Look out, Amgen, Allergan, et al. PBMs are eyeing your forthcoming meds for pricing pressure—and as hep C drugmakers know, consequences can be brutal.
Former Teva Generics CEO Siggi Olafsson is back in the copycat game—this time, as the new CEO of Jordan’s Hikma Pharmaceuticals.
Astellas buys Universal Cells, Teva is affected by Celltrion's manufacturing problem, Korea rolls out a digital health initiative.
Teva may be decimating its employee ranks and struggling under a mountain of debt, but Warren Buffett apparently likes what he sees.
Purdue made a splash with its plans to stop marketing opioids this week, but Endo, Teva, Allergan and J&J had already quit.
Some drugmakers reap far more savings from tax reform than others—and some will actually have to pay more. Here's our report card.
Novartis’ copycat arm, Sandoz, needed a win. And it got a key one Tuesday with the approval of generic 40-mg Copaxone.
The impact of an FDA warning letter issued last month for a Celltrion plant in South Korea has broadened to Teva Pharmaceuticals.
Teva just went through a horrible year, today reporting a $17.5 billion operating loss in 2017, but execs said things will get worse before they get better.